They successfully developed a tumor-targeted therapeutic platform combining PTT and gene therapy by integrating CuS DENPs, arginine-glycine-aspartate (RGD) peptides, and plasmid DNA-encoding hypermethylation in cancer 1 (pDNA-HIC1). The gene discussed is HIC1; the disease is cancer.